Regeneron Pharmaceuticals (REGN) Revenue and Net Income History
Historical revenue, operating income and net income for Regeneron Pharmaceuticals (REGN) over the last 10 years. The current TTM revenue for Regeneron Pharmaceuticals as of February 16, 2018 is $5.87B.
|Medical||Medical - Biomedical and Genetics||$35.686B||$5.872B|
|Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma and has preclinical programs in other diseases and disorders.|